10-K: Immunocore Reports Strong Revenue Growth, Narrows Losses

Immunocore Holdings plc announced significant revenue growth for 2025, driven by its lead product KIMMTRAK, while also reducing its net loss, signaling progress in its commercialization and pipeline development.

Summary

• Immunocore Holdings plc reported total revenue of $400.0 million for the year ended December 31, 2025, a 29% increase from $310.2 million in 2024.
• Net loss for 2025 was $35.5 million, an improvement from a net loss of $51.1 million in 2024 and $55.3 million in 2023.
• Revenue from the sale of therapies, primarily KIMMTRAK, increased by 29% to $400.0 million in 2025, with strong growth in both the United States ($257.0 million) and Europe ($131.4 million).
• KIMMTRAK is now approved in 39 countries and commercially launched in 30, including the United States, Germany, and France.
• Research and development (R&D) expenses increased by 24% to $274.9 million in 2025, reflecting continued advancement of the pipeline, particularly for autoimmune programs and tebentafusp Phase 3 trials.
• Selling, general and administrative (SG&A) expenses rose to $165.4 million in 2025, up from $155.8 million in 2024, supporting global commercial expansion.
• The company completed a private offering of $402.5 million in convertible senior notes in February 2024, with net proceeds of $389.1 million, and repaid the Pharmakon loan in November 2024.
• As of December 31, 2025, cash and cash equivalents stood at $467.7 million, with marketable securities of $396.4 million, providing sufficient funds for at least 12 months of operations.
• Initial data from the Phase 1/2 STRIVE trial for IMC-M113V in HIV showed all doses were well tolerated, with three out of 15 evaluable patients demonstrating delayed viral rebound and/or viremia control during analytical treatment interruption, compared to a historical rate of 5%.
• A Clinical Trial Application (CTA) for IMC-S118AI, an autoimmune candidate for type 1 diabetes, was submitted in December 2025, with a Phase 1 trial expected to begin in the first half of 2026.
• The company plans to file a CTA or IND for IMC-U120AI, a CD1a-tethered PD1 agonist ImmTAAI therapy for atopic dermatitis, in the second half of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive. The significant revenue growth and reduction in net loss demonstrate strong commercial momentum for KIMMTRAK and improved financial health. The robust pipeline progression across oncology, infectious diseases, and autoimmune conditions, coupled with a solid cash position, indicates strong future potential despite ongoing R&D investments and management changes.

Positives

• Total revenue increased by 29% year-over-year to $400.0 million in 2025, demonstrating strong commercial execution.
• Net loss significantly narrowed to $35.5 million in 2025 from $51.1 million in 2024, indicating improved financial efficiency and path towards profitability.
• KIMMTRAK, the lead product, is approved in 39 countries and commercially launched in 30, showing broad market penetration.
• Advancement of multiple late-stage clinical programs, including three Phase 3 registrational trials for KIMMTRAK (TEBE-AM, ATOM) and brenetafusp (PRISM-MEL-301).
• Promising initial Phase 1/2 data for IMC-M113V in HIV, with some patients showing viral control, exceeding historical observation rates.
• Expansion of the ImmTAX platform into autoimmune diseases with two new candidates, IMC-S118AI and IMC-U120AI, progressing towards clinical trials.
• Strong liquidity position with $467.7 million in cash and cash equivalents and $396.4 million in marketable securities as of December 31, 2025.
• Successful completion of a $402.5 million convertible senior notes offering in February 2024, strengthening the capital structure.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $831.3 million as of December 31, 2025.
• Increased R&D expenses (up 24% to $274.9 million) and SG&A expenses (up to $165.4 million) reflect ongoing high costs of drug development and commercialization.
• Tina St. Leger, Chief Human Resources Officer, is resigning effective May 26, 2026.
• Dr. David Berman, EVP, Research and Development, is departing effective February 27, 2026, with no direct replacement sought, potentially impacting R&D leadership.
• A global recall for one batch of KIMMTRAK was initiated in June 2025 due to an unexpected result in routine stability testing, though expected to have no material impact on supply or financials.
• The company recorded a $14.7 million deferred tax expense in 2025 due to a valuation allowance on U.S. deferred tax assets, as profitability in the U.S. jurisdiction is not expected in the short term due to intercompany pricing changes.

Risks

• Significant losses incurred since inception, with no assurance of achieving or maintaining profitability.
• Ability to generate revenues from KIMMTRAK and other product candidates is subject to market acceptance, perceived safety and efficacy, and advantages over other therapies.
• Revenues from KIMMTRAK may be significantly reduced by existing and future drug pricing reforms, including rebates and potential changes in CMS policies.
• Substantial additional funding may be required to achieve business goals, and inability to obtain it on acceptable terms could delay or terminate product development.
• Heavy dependence on the ImmTAX platform; failure to successfully develop and commercialize platform or product candidates could harm the business.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, which may develop or commercialize drugs more successfully.
• Uncertainty in completing additional large-scale, pivotal clinical trials for product candidates, with potential for delays or termination.
• Novel mechanism of action and targets of product candidates may lead to greater R&D expenses, regulatory issues, or discovery of unknown adverse effects.
• Clinical product development is a lengthy, expensive, and uncertain process, with interim data subject to change.
• Failure to comply with manufacturing regulations could adversely affect financial results and condition, including potential recalls or regulatory enforcement actions.
• Reports of adverse events or safety concerns involving KIMMTRAK or product candidates could delay or prevent regulatory approvals or negatively impact sales.
• Ongoing regulatory obligations and continued review post-approval may result in significant additional expense, post-market study requirements, or market withdrawal.
• Compromised information technology systems or data, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Inability to adequately protect proprietary technology or obtain, maintain, protect, and enforce patent and other intellectual property protection could impair commercialization.
• Third parties may initiate legal proceedings alleging infringement of intellectual property rights, leading to uncertain outcomes and material adverse effects.
• Regulatory pathways are difficult to predict, and unanticipated clinical trials may be required, depending on data obtained.
• Future success depends on ability to retain key executives and experienced scientists and to attract, retain, and motivate qualified personnel.
• Existing and future therapeutic collaborations are important; inability to maintain or unsuccessful collaborations could adversely affect the business.
• Economic, political, regulatory, and other risks associated with international operations, including exchange rate fluctuations and geopolitical tensions (e.g., Ukraine war, Middle East conflict).
• Potential product liability claims if product candidates harm patients, leading to substantial liability and costs.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Risk of clinical hold at any time based on evaluation of data and information submitted to regulatory authorities.
• Developing product candidates in combination with other therapies exposes the company to additional risks related to those therapies.
• Failure to achieve projected development and commercialization goals within expected timeframes could harm the business.
• Prioritization of certain product candidates over others due to limited resources may prove to be incorrect.
• FDA and similar foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Inability to obtain or maintain Orphan Drug Designation or Breakthrough Therapy Designation for product candidates could limit benefits.
• Changes in healthcare laws, regulations, or policies, including unfavorable pricing restrictions, could adversely affect development and commercialization.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud, and abuse laws, which could expose the company to significant penalties.
• Inability to file applications to commence additional clinical trials on expected timelines or obtain permission to proceed.
• Changes in funding for regulatory authorities could hinder their ability to perform normal functions, negatively impacting the business.
• Potential for increased costs in offering and maintaining competitive salaries due to inflation.
• Difficulties in managing growth due to expansion of development, commercial, and regulatory capabilities.
• Risks associated with future acquisitions or strategic partnerships, including increased capital requirements, dilution, debt, and integration challenges.
• Insurance policies may not cover all business risks, leaving the company exposed to significant uninsured liabilities.
• Indebtedness from convertible senior notes may limit financial flexibility and dilute ownership interests upon conversion.
• Provisions in the indenture governing the notes may delay or prevent beneficial takeover attempts.
• Lack of sustained active trading market for ADSs and high volatility in trading price.
• Executive officers, directors, and principal shareholders have significant control over matters submitted to shareholders for approval.
• Potential requirement to repurchase shares held by the Bill & Melinda Gates Foundation if global access commitments are breached, impacting liquidity.
• Shareholder protections under the U.K. City Code on Takeovers and Mergers may not apply.
• Shareholder rights may differ from those of a U.S. corporation, and certain capital structure decisions require shareholder approval.
• Exclusive forum provisions in articles of association may limit shareholders' ability to bring claims in preferred judicial forums.
• ADS holders may not be entitled to a jury trial for claims under the deposit agreement.
• ADS holders may not receive distributions on ordinary shares if illegal or impractical to make them available.
• No anticipated cash dividends in the foreseeable future; capital appreciation is the sole source of gains.
• Claims of U.S. civil liabilities may not be enforceable against the company due to its English incorporation and non-U.S. based management/assets.
• Inability to use net operating loss and tax credit carryforwards or benefit from favorable U.K. tax legislation.
• Changes and uncertainties in the tax system in operating countries could adversely affect financial condition and reduce net returns to shareholders.

Future Outlook

Immunocore's strategic priorities for 2026 include growing KIMMTRAK sales and preparing for new melanoma indications through ongoing Phase 3 trials (TEBE-AM and ATOM), expanding beyond melanoma into other tumor types with multiple Phase 1 readouts for PRAME bispecific candidates (brenetafusp and IMC-P115C) in ovarian and NSCLC, and realizing growth opportunities beyond oncology by advancing autoimmune disease candidates (IMC-S118AI and IMC-U120AI) into the clinic and continuing dose escalation in the HIV trial (IMC-M113V). The company expects to complete enrollment in the TEBE-AM trial in the first half of 2026 with topline data as early as the second half of 2026, and anticipates additional MAD data from the STRIVE trial in HIV in the second half of 2026. Initial data from the IMC-R117C trial is expected in 2027.

Management Comments

• We believe that these tumor types have large addressable patient populations and significant unmet need.
• We will also continue pioneering immunotherapy and unlocking the full potential of our platform to generate transformative treatments for patients, by using different targeting mechanisms and immune effectors for next-generation bispecific therapies.
• We believe IMC-S118AI has the potential to provide a differentiated option for treatment with advantages of tissue-specific down modulation without immunosuppression.
• We expect that our existing cash and cash equivalents with the inclusion of expected revenue for KIMMTRAK will provide sufficient funds to continue to meet our liabilities as they fall due and for at least 12 months from the issuance of our Annual Report.

Industry Context

StockSavvy.ai notes Immunocore's continued focus on its ImmTAX platform positions it within the competitive and rapidly evolving biotechnology sector, particularly in oncology, infectious diseases, and autoimmune conditions. The company's strategy to expand KIMMTRAK's indications and geographic reach, alongside advancing a deep pipeline, aligns with broader industry trends of maximizing approved assets while diversifying therapeutic areas. The increasing R&D investment is typical for a commercial-stage biotech aiming for pipeline growth. The challenges of drug pricing reforms and intense competition from established players like Bristol Myers Squibb, Regeneron, and emerging biotechs developing TCR-based therapies highlight the high-stakes environment Immunocore operates in. The company's move into autoimmune diseases with novel PD1 agonist ImmTAAI therapies also reflects a trend towards precision immunomodulation beyond traditional oncology applications.

Comparison to Industry Standards

• Immunocore's KIMMTRAK is the first approved therapy in metastatic uveal melanoma (mUM), establishing a new standard in this indication. Competitors like Delcath Systems, Inc. (HEPZATO KIT) and Ideaya Biosciences are also active in melanoma, with Ideaya Biosciences anticipating Phase 2/3 trial readouts in HLA-A*02:01 negative mUM in 2026, and Replimune Group Inc. conducting Phase 2/3 trials in immune-checkpoint naive UM.
• In cutaneous melanoma, Immunocore's brenetafusp + nivolumab combination in the PRISM-MEL-301 Phase 3 trial competes with established therapies and pipeline candidates from companies such as Regeneron (cemiplimab and fianlimab), Iovance (lifileucel and pembrolizumab), Immatics (IMA203 TCR-T), and Moderna (mRNA4157 vaccine).
• Immunocore's PRAME-targeted brenetafusp and IMC-P115C face competition from Immatics, TScan Therapeutics, Inc., and Replay Therapeutics, Inc., who are also conducting Phase 1 trials of PRAME-directed cellular therapies or bispecifics.
• In HIV, Immunocore's IMC-M113V aims for a functional cure, differentiating itself from the numerous existing antiretroviral therapies (ART) that suppress the virus but do not cure it. Competitors in the cure space are generally in early-stage clinical trials.
• For chronic HBV, IMC-I109V's observed reduction in HBsAg levels is a key indicator of resolved infection, a goal that most existing life-long antiviral therapies do not achieve, positioning it against a crowded field of suppressive treatments and prophylactic vaccines.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any arbitration or legal proceeding that, if determined adversely, would have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• The company has a global access commitments agreement with the Bill & Melinda Gates Foundation, a shareholder, requiring certain actions to support the Gates Foundation's mission, including making products available at an affordable price in developing countries. In the event of certain defaults, the Gates Foundation has the right to sell or require the company to buy back its shareholdings, with potential compensation obligations if a change in control occurs at a higher valuation within 12 months.

Stakeholder Impact

• **Shareholders:** Positive impact from strong revenue growth and reduced net loss, indicating improved financial performance. Potential dilution from future capital raises or conversion of convertible notes. Risk of share price volatility due to market factors and clinical trial outcomes. Potential for limited voting rights for ADS holders.
• **Patients:** Positive impact from the continued commercialization of KIMMTRAK for mUM and the advancement of pipeline candidates in oncology, infectious diseases (HIV, HBV), and autoimmune diseases (Type 1 Diabetes, Atopic Dermatitis), offering new therapeutic options.
• **Employees:** Increased R&D and SG&A expenses suggest continued investment in personnel and growth opportunities. Management changes (CHRO, EVP R&D) could impact organizational structure and leadership, but the company emphasizes retaining qualified personnel.
• **Customers (Distributors/Healthcare Providers):** Continued supply of KIMMTRAK and expansion into new territories. Impact of drug pricing reforms and reimbursement policies could affect product accessibility and profitability for distributors.
• **Creditors (Convertible Note Holders):** Fixed interest payments on convertible senior notes. Potential for conversion into ADSs, affecting ownership structure. Repayment of Pharmakon loan reduces debt burden.

Next Steps

• Complete patient enrollment in the TEBE-AM Phase 3 advanced melanoma trial in the first half of 2026.
• Expect topline data from the TEBE-AM trial as early as the second half of 2026.
• Present data from brenetafusp combinations in ovarian and lung cancer in the second half of 2026.
• Present data from the PRAME half-life extended candidate (IMC-P115C) in the second half of 2026.
• Report additional Multiple Ascending Dose (MAD) data from the STRIVE trial for IMC-M113V in HIV in the second half of 2026.
• Initiate the Phase 1 clinical trial for IMC-S118AI (PPI x PD1) in type 1 diabetes in the first half of 2026.
• Submit a CTA or IND for IMC-U120AI (CD1a x PD1) for atopic dermatitis in the second half of 2026.
• Determine next steps for the IMC-I109V (HBV) program in 2026 after completing the SAD portion of the trial.
• Complete enrollment in the ATOM registrational Phase 3 trial for adjuvant uveal melanoma in 2028.
• Present initial data from the IMC-R117C (PIWIL1-A02) trial in 2027.

Key Dates

Recommendation

Immunocore demonstrates strong commercial execution with significant revenue growth from KIMMTRAK and a notable reduction in net losses, indicating a positive trajectory towards profitability. The robust pipeline, particularly the advancement of multiple Phase 3 trials and promising early-stage data in infectious and autoimmune diseases, presents substantial long-term growth potential. However, the company still operates at a net loss, faces intense competition, and is subject to significant regulatory and market risks inherent in the biotechnology sector. The recent management changes, while not immediately critical, introduce some uncertainty. Given the strong performance but also the inherent risks and long development cycles, a 'hold' recommendation is appropriate for investors to monitor continued commercial success, pipeline progression, and the impact of macroeconomic and regulatory factors.

Keywords

Immunocore, KIMMTRAK, ImmTAX, TCR, Oncology, Uveal Melanoma, Metastatic Melanoma, Autoimmune Diseases, Infectious Diseases, HIV, HBV, Brenetafusp, IMC-P115C, IMC-R117C, IMC-M113V, IMC-S118AI, IMC-U120AI, Biotechnology, Pharmaceutical, Clinical Trials, Regulatory Approval, SEC Filing, 10-K, Financial Results, Revenue Growth, Net Loss, Pipeline Development, Drug Pricing, Intellectual Property, Corporate Governance